clinical trial · NCT05215418
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
Blood PressureVI-0521PhenterminePlacebo
brief summary
The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an active control (phentermine 30 mg).
started
Jan 25, 2022
primary completion
Apr 11, 2023
completion
Apr 17, 2023
last updated
Jul 17, 2024
official title
A Multicenter, Randomized, Double-Blind Study to Compare the Effects of VI-0521,Phentermine, and Placebo on Ambulatory Blood Pressure in Overweight or Obese Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol